{"Clinical Trial ID": "NCT00246571", "Intervention": ["INTERVENTION 1:", "- Sunitinib", "SU011248 (Sutent [sunicitinib malate, hereinafter referred to as sunitinib]) oral capsules, 37.5 milligrams (mg) once daily (QD) in a continuous diet, expressed in 3-week cycles. One-week treatment rests and dose reductions allow dose-limit toxicity (DLT).", "INTERVENTION 2:", "Care standard", "One of the following regimens was administered (at the discretion of the investigator): oral capecitabine 1000-1250 mg/m^2 IDB Days 1 to 14, every 3 weeks; vinorelbine 25-30 mg/m^2 IV infusion fast or 60-80 mg/m^2 weekly oral infusion, expressed in 3-week cycles; docetaxel 75-100 mg/m^2 IV infusion every 3 weeks; paclitaxel 175-200 mg/m^2 IV infusion every 3 weeks; paclitaxel 80-90 mg/m^2 weekly injection, expressed in 3-week cycles or 3 weeks of treatment followed by a week of rest; gemcitabine 800-1250 mg/m^2 IV infusion, Days 1 and 8 every 3 weeks."], "Eligibility": ["Incorporation criteria:", "Recurrent or metastatic breast cancer", "Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative status", "Previous treatment with anthracycline and taxane as part of an adjuvant or advanced disease", "\u2022 Release after adjuvant chemotherapy within 6 months of last treatment and/or receive one or two chemotherapy treatments for advanced disease", "- Exclusion criteria:", "More than two chemotherapy treatments for advanced disease", "\u2022 Uncontrolled/symptomatic spread of cancer in the brain"], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "The PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncological assessment data (where data meet progressive disease criteria [PD]), or from adverse event data (where the result was \"dead\").", "Timeline: Basic data, every 6 weeks until disease progression or death (up to 3 years after first dose)", "Results 1:", "Title of the arm/group: Sunitinib", "Description of the arm/group: SU011248 (Sunitinib malate, hereinafter referred to as sunitinib) oral capsules, 37.5 milligrams (mg) once daily (QD) in a continuous diet, expressed in cycles of 3 weeks. One week's treatment rests and dose reduction is used to limit toxicity (DLT).", "Total number of participants analysed: 113", "Median (95% confidence interval)", "Unit of measure: Month Evaluation of basic radiology laboratory: 2.0 (1.5 to 2.8)", "\u25cf Investigator's assessment: 1.7 (1.5 to 2.6)", "Results 2:", "Title of Arm/Group: Standard of Care", "One of the following regimens was administered (at the discretion of the investigator): oral capecitabine 1000-1250 mg/m^2 BID Days 1 to 14, every 3 weeks; vinorelbine 25-30 mg/m^2 infusion IV rapid or 60-80 mg/m^2 infusion weekly, expressed in 3-week cycles; docetaxel 75-100 mg/m^2 infusion IV every 3 weeks; paclitaxel 175-200 mg/m^2 infusion IV every 3 weeks; paclitaxel 80-90 mg/m^2 injection weekly, expressed in 3-week cycles or 3 weeks of treatment followed by a week of rest; gemcitabine 800-1250 mg/m^2 infusion IV, Days 1 and 8 every 3 weeks.", "Total number of participants analysed: 104", "Median (95% confidence interval)", "Unit of measure: Month Basic radiology laboratory evaluation: 2.7 (1.7 to 2.8)", "\u25cf Investigator's assessment: 2.5 (1.4 to 2.9)"], "Adverse Events": ["Undesirable Events 1:", "Total: 40/110 (36.36 per cent)", "Anemia * 3/110 (2.73%)", "Intravascular coagulation disseminate * 1/110 (0.91%)", "Febrile neutropenia * 2/110 (1.82%)", "Leucopenia * 0/110 (0.00 %)", "Pancytopenia * 1/110 (0.91%)", "Thrombocytopenia * 2/110 (1.82%)", "Atrial fibrillation * 1/110 (0.91%)", "Cardiac arrest * 1/110 (0.91%)", "* 1/110 (0.91%)", "Cardiopulmonary impairment * 1/110 (0.91%)", "Adverse Events 2:", "Total: 21/103 (20.39%)", "Anemia * 0/103 (0.00 %)", "Disseminate intravascular coagulation * 0/103 (0.00 %)", "Febrile neutropenia * 2/103 (1.94%)", "Leukopenia * 1/103 (0.97%)", "Pancytopenia * 0/103 (0.00 %)", "Thrombocytopenia * 0/103 (0.00 %)", "Atrial fibrillation * 1/103 (0.97%)", "Cardiac arrest * 0/103 (0.00 %)", "Heart failure * 0/103 (0.00 %)", "Cardiopulmonary impairment * 0/103 (0.00 %)"]}